Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer
Appointment of experienced pre-clinical CRO specialist to support accelerated expansion into key global markets
Cambridge, UK, 23 July 2024: Metrion Biosciences Limited (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing…
Genetically engineered iPSCs offer improved efficiency and cost savings.
AMSBIO has launched a range of genetically engineered Induced Pluripotent Stem Cells (iPSCs) developed to provide improved model fidelity over cell lines and biochemical assays used for drug discovery and cell therapy research.
These iPSC cell lines offer improved efficiency and cost savings compared to animal models, enhancing high-throughput reporter lines, human disease models and toxicity screening. The new range includes iPSCs genetically engineered to express Cas9 either constitutively or upon doxycyclin…
Astex Pharmaceuticals is pleased to share the below news which was today Issued by its collaborator The Institute of Cancer Research, London,
MHRA approves first-in-class breast cancer drug
• MHRA approves first-in-class drug Truqap (capivasertib) in combination with fulvestrant for treating HR-positive, HER-2 negative locally advanced breast cancer with specific biomarker alterations (PIK3CA, AKT1 or PTEN) alterations following recurrence or progression on or after an endocrine based regimen
• Capivasertib was discovered by AstraZeneca subsequent to a collaboration with Astex Pharmaceuticals…
Protagene has added cell based bioassay driven structure-function correlation to its extensive portfolio of MS and biophysical methods. Non GMP assays are available immediately, with GMP level assays becoming available in August.
To discuss this or any other analytical requirements, please contact colin.crowley@protagene.com
Cambridge, UK – July 17th 2024 - The Cambridge Crystallographic Data Centre (CCDC) is excited to highlight that its CSD-Particle suite of advanced informatics tools is now being actively used to revolutionize the understanding of particle behaviour and surface properties in pharmaceutical and fine chemical manufacturing. The suite provides easy to use digital methods to enhance the efficiency of product formulation and reduce manufacturing costs.
A study published in Crystal Growth & Design, "Surface Analysis - From Crystal Structures to Particle Properties," highlights the suite’s…
Pharmaron's DMPK Insights Podcast Episode #8: “It’s ‘All-go’ with Oligos: Challenges and Opportunities in LC-MS of Therapeutics.”
Explore the latest episode of Pharmaron's DMPK Insights Podcast Series: “It’s ‘All-go’ with Oligos: Challenges and Opportunities in LC-MS of Therapeutics.”Join experts Robert MacNeill, Professor Michael Bartlett and Dr. Guilherme (Gui) Guimaraes as they delve into the dynamic world of oligonucleotide LC-MS. Discover the key challenges, the critical importance of sensitivity in these assays, and the innovative analytical approaches and technologies being developed…
Menopause care provider Minter Hormone Health wins Femtech and Women’s Health competition
The Femtech & Women’s Health edition of ‘Discovery Spark’ supports early stage businesses working to close the gender health gap
Sandwich, Kent, UK / 15th July 2024 / Discovery Park has announced Minter Hormone Health as the winner of the Discovery Spark FemTech and Women’s Health Prize, following a competitive pitch process to three expert panels.
The Women’s Health startup will now receive a prize package worth over £50K, including one year of lab or office space at Discovery…
Anglia Innovation Partnership, the campus management organisation at Norwich Research Park, hosted its latest Enterprise Tuesday event on Tuesday 11 June at the John Innes Conference Centre, showcasing novel technology platforms and debating the value of ‘science push and industry pull’ activity in the cluster.
The event entitled ‘Research and Technology Platforms Open for Innovative Business’ presented case studies to explain how the specialist facilities were created, at the campus, how they are used in publicly funded research, on the campus, and their current and future potential…
CCDC Scientist Awarded Prestigious BACG Young Scientists Award
Dr Pietro Sacchi Wins the Award for Ground-Breaking Work Providing Practical Solutions to Long-Standing Challenges in Drug Development and Manufacturing
Cambridge, UK – 12 July 2024 – We are pleased to announce that Dr Pietro Sacchi, Research and Application Scientist at the CCDC, has been awarded the British Association for Crystal Growth (BACG) Young Scientists Award for his exceptional research on the HIV drug ritonavir.
The BACG Young Scientists Award is granted annually to a candidate who has made the most significant…
The pharmaceutical landscape is evolving rapidly, and staying ahead requires a deep understanding of the current trends and challenges. This comprehensive report provides a critical analysis of the drug development industry, focusing on the health of pipelines, the strategic focus of biotechs and pharmacos, and the capacity of regulators like the FDA to manage the influx of novel therapies.
Download now.